Athebio

Pre-clinical

Zurich, SwitzerlandFounded 2017athebio.com

Athebio is a privately held biotech company founded in 2019, leveraging its Athebody® DARPin platform to empower drug developers with a versatile, 'plug & play' scaffold for creating superior targeted therapeutics. The company's mission is to explore and unleash the therapeutic potential of repeat proteins, offering partners a technology characterized by high specificity, solubility, stability, and ease of manufacturing. Athebio's business model is centered on strategic partnerships and technology transfer, as evidenced by its collaboration with POINT Biopharma to develop targeted radioligands.

Founded

2017

Employees

20-50

Focus

BiologicsAntibodies

AI Company Overview

Technology Platform

The Athebody® platform is a proprietary technology based on Designed Ankyrin Repeat Proteins (DARPins), a small, stable, and modular protein scaffold used to create highly specific binders for targeted biotherapeutics across multiple modalities.

Funding History

Total raised: $27.7M

Series A$22MForbionNov 15, 2022

Seed$2.5MUndisclosedJun 15, 2021

Seed$3.2MHigh-Tech GründerfondsSep 15, 2020

Opportunities

Significant opportunities exist in the rapidly growing fields of targeted radionuclide therapy and multi-specific biologics, where Athebio's DARPin platform offers distinct advantages in stability and modularity.

Expanding its partnership portfolio with pharmaceutical and biotech companies across these and other modalities (e.g., cell & gene therapy targeting) is the primary growth vector.

Risk Factors

Key risks include intense competition from other scaffold platforms and internal big pharma capabilities, dependence on securing and successfully executing partnerships for revenue, and the inherent technological and clinical development risks of novel biologic modalities that could impact partner programs and Athebio's reputation.

Competitive Landscape

Athebio's main competitor in the DARPin space is Molecular Partners AG. It also competes with companies using alternative scaffolds like Affibodies, Adnectins, and nanobodies. Differentiation is based on its efficient discovery engine, partnership-focused 'plug & play' model, and application in emerging areas like targeted radiotherapy.